Clinical Study on Endometrial Receptivity

NCT ID: NCT03687021

Last Updated: 2018-09-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-10

Study Completion Date

2018-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

to explore the differential expression of miRNA in the implantation window of patients with endometriosis and the time of progesterone and route of administration on planting window

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Receptivity;RNA; Progesterone

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

endometriosis

tissue biopsy from patients (n=10) with endometriosis

Group Type NO_INTERVENTION

No interventions assigned to this group

without endometriosis

tissue biopsy from patients (n=10) without endometriosis

Group Type NO_INTERVENTION

No interventions assigned to this group

Intramuscular progesterone

Intramuscular progestin(20mg)

Group Type EXPERIMENTAL

Progesterone

Intervention Type DRUG

Different routes of administration of progesterone; Whether there is endometriosis

vaginal progesterone

vaginal progestin (90mg)

Group Type EXPERIMENTAL

Progesterone

Intervention Type DRUG

Different routes of administration of progesterone; Whether there is endometriosis

oral progesterone

oral progestin(40mg)

Group Type EXPERIMENTAL

Progesterone

Intervention Type DRUG

Different routes of administration of progesterone; Whether there is endometriosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Progesterone

Different routes of administration of progesterone; Whether there is endometriosis

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The endometriosis group treatment group: Previous laparoscopy or laparotomy confirmed endometriosis;Regular menstruation, no rule vaginal bleeding;Ovarian reserve function is normal.

control group: Laparoscopic bilateral salpingectomy was performed due to ectopic pregnancy, benign ovarian changes and other reasons, with the exception of endometriosis during the operation.Regular menstruation, no rule vaginal bleeding;Ovarian reserve function is normal
2. progesterone group Women with hypothalamic amenorrhea or premature ovarian failure;Ages 18-40

Exclusion Criteria

Patients with medical complications
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking Union Medical College Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Qi Yu, profssor

Role: primary

18612671865

Xi Wang

Role: backup

13121133350

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

yuqi03029

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.